Skip to main content
SpringerLink
Log in

Hypertonologie 2007–2008

Hypertension 2007–2008

  • UPDATE
  • Published:
Medizinische Klinik Aims and scope Submit manuscript

Zusammenfassung

Die arterielle Hypertonie ist einer der wichtigsten Risikofaktoren für Erkrankungen des kardiovaskulären Systems und der Niere. Trotz jahrelanger Anstrengungen ist der Stand ihrer Diagnostik und Behandlung nach wie vor nicht optimal. Diesbezüglich haben die Europäische Hypertoniegesellschaft und die Deutsche Hochdruckliga aktuelle Leitlinien erarbeitet. Darüber hinaus ist in den letzten 2 Jahren eine Reihe von großen randomisiert-kontrollierten klinischen Studien zum Thema publiziert worden. Die dabei gewonnenen Erkenntnisse zum Stellenwert einer Kombinationstherapie aus Angiotensin-converting-Enzym-(ACE-)Inhibitoren und Calciumantagonisten, die ernüchternden Ergebnissen der ONTARGET-Studie, in der eine Kombinationstherapie aus ACE-Inhibitoren und Angiotensinrezeptorenblockern (ARBs) angewandt wurde, der Nutzen einer antihypertensiven Therapie bei sehr alten Patienten sowie die Einführung und Zulassung einer neuen Klasse blutdrucksenkender Arzneimittel, der oralen Renininhibitoren, werden die alltägliche Praxis enorm beeinflussen. In der vorliegenden Übersicht werden diese und weitere Studien kurz vorgestellt und die praktisch-therapeutische Bedeutung diskutiert.

Abstract

Hypertension still represents a leading cause of mortality worldwide and a main modifiable risk factor for cardiovascular, cerebrovascular and renal diseases. Therefore, guideline writing groups have proposed new recommendations regarding diagnosis and treatment. Nevertheless, a series of large-scale clinical trials have been published thereafter. Their results, namely the risk associated with the combination of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), the benefits of an initial therapy with a fixed-dose combination of calcium channel blocker and ACE inhibitor, the effectiveness of blood pressure reduction in patients > 80 years, and the introduction of oral renin inhibitors in the market will enormously impact clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13.

    Article  PubMed  Google Scholar 

  2. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347–60.

    Article  PubMed  Google Scholar 

  3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–23.

    PubMed  Google Scholar 

  4. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69–75.

    Article  PubMed  CAS  Google Scholar 

  5. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–87.

    Article  PubMed  CAS  Google Scholar 

  6. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004;363:2049–51.

    Article  PubMed  CAS  Google Scholar 

  7. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713–9.

    Article  PubMed  Google Scholar 

  8. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952–61.

    Article  PubMed  CAS  Google Scholar 

  9. Yusuf S, Teo KK, Pague J, et al., ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–59.

    Article  PubMed  CAS  Google Scholar 

  10. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547–53.

    Article  PubMed  CAS  Google Scholar 

  11. Phillips CO, Kashani A, Ko DK, et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007;167:1930–6.

    Article  PubMed  CAS  Google Scholar 

  12. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30–48.

    PubMed  Google Scholar 

  13. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829–40.

    Article  PubMed  CAS  Google Scholar 

  14. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417–28.

    Article  PubMed  CAS  Google Scholar 

  15. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52.

    Article  PubMed  CAS  Google Scholar 

  16. Yusuf S, Teo K, Anderson C, et al., Telmisartan Ran domised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174–83.

    Article  PubMed  CAS  Google Scholar 

  17. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–41.

    Article  Google Scholar 

  18. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208–19.

    Article  PubMed  CAS  Google Scholar 

  19. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225–37.

    Article  PubMed  CAS  Google Scholar 

  20. Chobanian AV. Clinical practice. Isolated systolic hypertension in the elderly. N Engl J Med 2007;357:789–96.

    Article  PubMed  CAS  Google Scholar 

  21. Turnbull F, Neal B, Ninomiya T, et al., Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121–3.

    Article  PubMed  CAS  Google Scholar 

  22. Turnbull F, Blood Pressure Lowering Treatment Trialists’ Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527–35.

    Article  PubMed  CAS  Google Scholar 

  23. Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup metaanalysis of randomised controlled trials. INDANA Group. Lancet 1999;353:793–6.

    Article  CAS  Google Scholar 

  24. Oates DJ, Berlowitz DR, Glickman ME, et al. Blood pressure and survival in the oldest old. J Am Geriatr Soc 2007;55:383–8.

    Article  PubMed  Google Scholar 

  25. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887–98.

    Article  PubMed  CAS  Google Scholar 

  26. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;370:591–603.

    Article  PubMed  CAS  Google Scholar 

  27. Fagard RH, Staessen JA, Thijs L, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med 2007;167:1884–91.

    Article  PubMed  Google Scholar 

  28. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201–7.

    Article  PubMed  CAS  Google Scholar 

  29. Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008;31:353–60.

    Article  PubMed  CAS  Google Scholar 

  30. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592–7.

    Article  PubMed  CAS  Google Scholar 

  31. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414–31.

    Article  PubMed  CAS  Google Scholar 

  32. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–91.

    Article  PubMed  CAS  Google Scholar 

  33. Muller DN, Luft FC. Renin receptor blockade: a better strategy for renal protection than renin-angiotensin system inhibition? Curr Hypertens Rep 2008;10:405–9.

    Article  PubMed  CAS  Google Scholar 

  34. Luft FC, Weinberger MH. Antihypertensive therapy with aliskiren. Kidney Int 2008;73:679–83.

    Article  PubMed  CAS  Google Scholar 

  35. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20:11–20.

    Article  PubMed  CAS  Google Scholar 

  36. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190–8.

    Article  PubMed  CAS  Google Scholar 

  37. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217–26.

    Article  PubMed  CAS  Google Scholar 

  38. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, doubleblind trial. Lancet 2007;370:221–9.

    Article  PubMed  CAS  Google Scholar 

  39. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433–46.

    Article  PubMed  CAS  Google Scholar 

  40. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417–27.

    PubMed  CAS  Google Scholar 

  41. Ichihara A, Suzuki F, Nakagawa T, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006;17:1950–61.

    Article  PubMed  CAS  Google Scholar 

  42. Ichihara A, Kaneshiro Y, Takemitsu T, et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006;47:894–900.

    Article  PubMed  CAS  Google Scholar 

  43. Luft FC. Renin and its putative receptor remain enigmas. J Am Soc Nephrol 2007;18:1989–92.

    Article  PubMed  CAS  Google Scholar 

  44. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med 2006;355:385–92.

    Article  PubMed  CAS  Google Scholar 

  45. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839–45.

    Article  PubMed  CAS  Google Scholar 

  46. Hermida RC, Ayala DE, Fernandez JR, et al. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 2008;51:69–76.

    Article  PubMed  CAS  Google Scholar 

  47. Tissot AC, Maurer P, Nussberger J, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008;371:821–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Hannover, Germany

    Hermann Haller

  2. Abteilung für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover, Germany

    Christos Chatzikyrkou

Authors
  1. Christos Chatzikyrkou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Menne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hermann Haller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christos Chatzikyrkou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chatzikyrkou, C., Menne, J. & Haller, H. Hypertonologie 2007–2008. Med Klin 104, 614–621 (2009). https://doi.org/10.1007/s00063-009-1133-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00063-009-1133-4

Schlüsselwörter:

Key Words:

Search

Navigation